PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Metrics, Inc.

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Metrics Contract Services Scientist Awarded Patent for Zero-order Release Tablet Technology - Dr. Brad Gold, vice president of pharmaceutical development, has received a U.S. patent for his intellectual property about controlled release technology [ASX: MYX] - MetricsInc.com
Metrics Contract Services Scientist Awarded Patent for Zero-order Release Tablet Technology

 

NewswireToday - /newswire/ - Greenville, NC, United States, 2014/10/28 - Dr. Brad Gold, vice president of pharmaceutical development, has received a U.S. patent for his intellectual property about controlled release technology [ASX: MYX] - MetricsInc.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

An expert scientist in pharmaceutical formulation development at Metrics Contract Services has been awarded a patent for intellectual property about controlled release technology.

The U.S. Patent and Trademark Office awarded Dr. Thomas B. “Brad” Gold a patent (No. 8,858, 993) for his application,“Coated tablets with zero-order or near zero-order release kinetics.”

Gold’s intellectual property centers on formulation development technology that allows for the steady, continuous release of active pharmaceutical ingredient (API) during a particular duration of time, so that a patient won’t experience variations or spikes of the medication’s therapeutic benefit.

“For a drug with a 12-hour release profile, for example, the tablet would release 100 percent of the API steadily throughout that time period without any drop offs or spikes, which sometimes occur with other modified release technologies,” Gold explained. “This is very advantageous for maintenance drugs and chronic therapies such as heart medications that need to reach a steady state in the patient’s bloodstream as soon as possible and remain there.”

Gold’s patent application builds upon osmotic techniques used to deliver soluble and insoluble large- or small-molecule drugs. Heretofore, true osmotic delivery relied on a matrix tablet with complex manufacturing needs such as, for example, the application of a solvent for the coating, the need to drill an orifice into the coating, and specialized equipment.

“The manufacturing of osmotic tablets is difficult, not very practical and expensive -- and for that reason, not many companies do it,” Gold explained.

By contrast, Gold’s innovation provides osmotic-like delivery benefits without the accompanying manufacturing challenges. Gold’s patented zero-order release technology uses direct compression, three to five excipients plus the active pharmaceutical ingredient (API), and a much simpler coating so that the tablet behaves similarly to an osmotic release tablet.

“Our technology offers the advantage of ease of manufacturing using standard industry processes and equipment,” he said.

John S. Ross, executive vice president of Metrics, said the patent reflects the kind of thoughtful scientific leadership that Gold and his colleagues apply to their work each day. The formulation development scientists at Metrics offer a depth of relevant experience that enables them to identify solutions to clients’ most challenging pharmaceutical projects, he said.

“For 20 years, pharma companies have consistently turned to Metrics for help in effectively delivering the full therapeutic benefit of their latest drug discoveries,” Ross said. “The reason they come back to us time and again is because we deliver sound and practical science. I congratulate Brad on this most impressive accomplishment.”

About Metrics Contract Services
Metrics Contract Services (metricsinc.com) is a full-service pharmaceutical development and manufacturing organization serving clients worldwide. We deliver proven scientific and operational excellence for solid oral dosage forms.

Our areas of expertise include quality formulation development; first-time-in-man formulations; Phase I-III clinical trial materials manufacturing; and analytical method development and validation services leading to commercial scale manufacturing. Our technical capabilities include highly potent, cytotoxic and unstable compounds; DEA Schedule II-V controlled substances; and products with poor bioequivalence, for which we offer an impressive propriety portfolio of advanced delivery methods.

Located in Greenville, N.C., Metrics Contract Services is a proud member of the Mayne Pharma family. Learn more online.

About Mayne Pharma

Mayne Pharma is a publicly traded specialty pharmaceutical company listed on the Australian Securities Exchange. The company develops and manufactures branded and generic product globally either directly or through distribution partners while applying its drug-delivery expertise for contract development and manufacturing services.

Mayne Pharma has a 30-year track record of innovation and success in developing new oral drug delivery systems, and these technologies have been successfully commercialized in numerous products that have been marketed around the world. Mayne Pharma has drug development and manufacturing facilities in Salisbury, Australia, with expertise in formulating complex oral dose forms, including controlled substances, modified release products and inherently unstable compounds.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Metrics, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Metrics Contract Services Scientist Awarded Patent for Zero-order Release Tablet Technology

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

Metrics, Inc. | Mayne Pharma
Publisher Contact: Karen Stinneford - Sinclair-Co.com for Metrics 
919-833-9102 kys[.]sinclair-co.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Metrics, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Metrics, Inc. / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

Frost & Sullivan Commends Nemaura for Developing Superior Transdermal Drug Delivery Technology Platforms, the Memspatch and Micropatch
Greenphire Sponsors Second Annual Clinical Trial Agreements, Investigator Payments and Fair Market Value Meeting
Genentech’s Gazyva Helped People with Previously Untreated Follicular Lymphoma Live Significantly Longer
BD Announces Adoption of Windows 10 ‘Internet of Things’ for the Pyxis™ ES System
Greenphire Named to Deloitte 2016 Technology Fast 500™
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
BD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery
BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin
MDxHealth Announces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association
BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections
Greenphire Receives EU-US Privacy Shield Certification
The 2016 Georges Mathé Prize Recognizes Research on the Immunological Determinants of the Response to Breast Cancer Treatment
MDxHealth Announces Agreement with HIFU CLINIC Prostate Cancer Center for Distribution of SelectMDx in Poland
First Patient in Malaysia Receives TheraSphere™ Radioembolisation Therapy
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) Prefilled Syringe

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  JobsWare.com

Visit  BizJobs.com





 
  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)